AGTC is a technology company.
AGTC has raised $38.0M across 1 funding round.
AGTC has raised $38.0M in total across 1 funding round.
AGTC has raised $38.0M in total across 1 funding round.
AGTC's investors include MPM Capital, Robert Garland, OrbiMed, Osage University Partners, SR One, Tectonic Ventures, James Barrett.
Applied Genetic Technologies Corporation (AGTC) is a clinical-stage biotechnology company specializing in gene therapies for rare ophthalmologic genetic diseases, such as X-linked retinitis pigmentosa, achromatopsia, X-linked retinoschisis, and age-related macular degeneration.[3][2][7] It develops proprietary gene therapy platforms to deliver potentially long-lasting treatments, targeting orphan indications with high unmet needs in patients who currently lack effective options.[2][3] AGTC serves patients, researchers, and clinicians through its pipeline of investigational products in Phase 1/2 trials, with positive interim data reported in 2020 for retinitis pigmentosa and achromatopsia programs.[3] As a publicly traded entity (NASDAQ: AGTC) headquartered in Alachua, Florida, it had a market cap of around $26.62M as of recent data, reflecting its focus on transformative therapies amid biotech market challenges.[4][6][3]
Note: AGTC Genomics (agtcgenomics.com) appears as a separate entity focused on next-generation sequencing services, not the gene therapy firm; this profile centers on the biotechnology company confirmed as a "technology company" in the query context.[1][3]
Founded in 1999 in Alachua, Florida, AGTC emerged from advancements in genetic research to address unmet needs in rare eye diseases.[3] The company assembled a team of specialized experts in gene therapy, ophthalmology, and cutting-edge technologies, building strong ties with patient advocacy groups like the Foundation Fighting Blindness and Alpha One Foundation early on.[2][3] Pivotal moments include entering clinical trials—signaling a shift from preclinical work to human treatments—and key 2020 trial results showing promise in retinitis pigmentosa and achromatopsia, advancing its pipeline toward potential market approval.[2][3] By 2019, AGTC expanded through collaborations like its optogenetics partnership with Bionic Sight, enhancing its retinal therapy innovations.[3]
AGTC stands out in the gene therapy space through these key strengths:
AGTC rides the explosive growth in gene therapy and precision medicine, particularly for rare genetic disorders where traditional drugs fail, fueled by CRISPR advancements and regulatory nods like FDA approvals for ocular therapies.[2][3] Timing is critical amid a surge in optogenetics and AAV-based vectors, positioning AGTC to capitalize on market forces like rising biotech investments in orphan drugs (projected multi-billion market) and patient demand for sight-restoring treatments.[3][7] It influences the ecosystem by partnering with innovators like Bionic Sight and advocacy networks, democratizing access to trials and pushing standards for retinal gene therapies, though as a smaller player, it navigates funding volatility in public biotech.[3][2]
AGTC's path forward hinges on advancing Phase 1/2 data into pivotal trials and potential partnerships for commercialization, with trends like AI-driven trial design and expanded optogenetics likely accelerating progress.[3] Rising M&A in gene therapy (e.g., larger firms acquiring clinical assets) could boost its low market cap trajectory, evolving its influence from niche innovator to key player in blinding disease cures.[4][6][3] Watch for 2026 catalysts like new trial readouts—success here could restore sight to thousands, validating AGTC's bet on genomics-driven tech from its 1999 origins.[2]
AGTC has raised $38.0M across 1 funding round. Most recently, it raised $38.0M Series B in November 2012.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2012 | $38.0M Series B | MPM Capital, Robert Garland, OrbiMed, Osage University Partners, SR One, Tectonic Ventures, James Barrett |